14 March 2019

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon 

2019-03-14T10:04:41-07:00

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon 2019-03-14T10:04:41-07:00
3 February 2019

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

2019-02-03T11:06:16-07:00

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC2019-02-03T11:06:16-07:00
5 January 2019

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

2019-01-05T11:08:03-07:00

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer.

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?2019-01-05T11:08:03-07:00
22 November 2018

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

2018-11-22T12:55:52-07:00

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors2018-11-22T12:55:52-07:00